EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Inclusion Criteria:

* Pathologically confirmed stage IIIB \& IV non-small cell lung cancer other than squamous cell carcinoma

  * Patients with one or more measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
  * Locally diagnosed sensitive EGFR mutation positive (Exon 19 deletion or L858R)
  * ECOG performance 0\~1
  * Age ≥ 19 years and - No previous treatment

Adequate organ function by following:

* ANC ≥1,500/uL, hemoglobin ≥9.0g/dL, platelet ≥100,000/uL
* Serum bilirubin \< 1 x UNL, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, If Liver metastasis, Serum bilirubin \< 3 x UNL, AST (SGOT) and ALT (SGPT) \< 5 x UNL
* Serum Cr ≤ 1 x UNL
* Patients who have had undergone radiotherapy are acceptable if patients meet all of the following criteria:

  * No history of irradiation to pulmonary tumor lesions.
  * In case of palliative irradiation to bone lesions in lung: at least 12 weeks must have passed at the date of registration since the last irradiation of the sites.
  * In case of irradiation to non-pulmonary sites: at least two weeks must have passed at the date of inclusion since the last irradiation of the sites
* At the time of registration, at least the following period has passed since last date of the prior therapy or procedure:

  * Surgery(including exploratory/ examination thoracotomy): 4 weeks
  * Pleural cavity drainage: 1 weeks
  * Pleurodesis without anti-neoplastic agents (inclusive of BRM such as Picibanil): 2 week
  * Biopsy accompanied by incision (including thoracoscopic biopsy): 2 week
  * Procedure for trauma (exclusive of patients with unhealed wound): 2 weeks
  * Transfusion of blood, preparation of hematopoietic factor: 2 week
  * Puncture and aspiration cytology: 1 week
  * Other investigational product: 4 weeks
* Written informed consent form

Exclusion Criteria:

* • Previous history of malignancy within 3 years from study entry except treated non-melanomatous skin cancer, uterine cervical cancer in situ, or thyroid cancer

  * Prior chemotherapy or systemic anti-cancer therapy for metastatic disease but postoperative adjuvant or neoadjuvant therapy of 6 months or more previously is allowed
  * Patients who received previous treatment for lung cancer with drugs
  * Symptomatic or uncontrolled central nervous system (CNS) metastases
  * Patients with increased risk of bleeding, clinically significant cardiovascular diseases, a history of thrombosis or thromboembolism in the 6 months prior to treatment, gastrointestinal problems, and neurologic problems
  * Any significant ophthalmologic abnormality
  * Pre-existing parenchymal lung disease such as pulmonary fibrosis
  * Known allergic history of Erlotinib or Bevacizumab
  * Interstitial lung disease or fibrosis on chest radiogram
  * Active infection, uncontrolled systemic disease (cardiopulmonary insufficiency, fatal arrhythmias, hepatitis)
  * Pregnant or nursing women